|
1.
|
|
7 p, 730.8 KB |
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
/
Socié, Gérard (Hôpital Saint-Louis) ;
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Barlev, Arie (Atara Biotherapeutics) ;
Sanz, Jaime (Hospital Universitari i Politècnic La Fe de València) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Chevallier, Patrice (University Hospital of Nantes) ;
Fagioli, Franca (University of Turin) ;
Guzman-Becerra, Norma (Atara Biotherapeutics) ;
Kumar, Deepali (University Health Network) ;
Ljungman, Per (Karolinska University Hospital) ;
Pigneux, Arnaud (Centre Hospitalier Universitaire de Bordeaux) ;
Sadetsky, Natalia (Atara Biotherapeutics) ;
Yáñez San Segundo, Lucrecia (Instituto de Investigación Sanitaria Valdecilla) ;
Shadman, Mazyar (Fred Hutchinson Cancer Center) ;
Storek, Jan (University of Calgary) ;
Thirumalai, Dhanalakshmi (Atara Biotherapeutics) ;
Xing, Baodong (Atara Biotherapeutics) ;
Mohty, Mohamad (Sorbonne University) ;
Universitat Autònoma de Barcelona
Epstein-Barr virus-positive (EBV +) post-transplant lymphoproliferative disease (PTLD) is an ultra-rare and aggressive condition that may occur following allogeneic hematopoietic cell transplant (HCT) due to immunosuppression. [...]
2023 -  10.1038/s41409-023-02127-9
Bone marrow transplantation, Vol. 59 (october 2023) , p. 52-58
|
|
|
2.
|
|
12 p, 804.5 KB |
RIC versus MAC UCBT in adults with AML : A report from Eurocord, the ALWP and the CTIWP of the EBMT
/
Baron, Frédéric (University of Liege) ;
Ruggeri, Annalisa (Hôpital Saint-Antoine (Paris, França)) ;
Beohou, Eric (Hôpital Saint-Antoine (Paris, França)) ;
Labopin, Myriam (Hôpital Saint-Antoine (Paris, França)) ;
Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ;
Milpied, Noel (University of Bordeaux) ;
Michallet, Mauricette (Centre Hospitalier de Lyon Sud) ;
Bacigalupo, Andrea (Ospedale San Martino) ;
Blaise, Didier (Aix-Marseille Université) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Socié, Gérard (Hospital Saint-Louis) ;
Cornelissen, Jan J. (Erasmus Medical Center-Daniel den Hoed Cancer Center) ;
Schmid, Christoph (University of Munich) ;
Giebel, Sebastian (Gliwice Branch) ;
Gorin, Norbert-Claude (Hospital Saint Antoine) ;
Esteve, Jordi (Hematology. Hospital Clinic) ;
Ciceri, Fabio (Ospedale San Raffaele) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Mohty, Mohamad (UMRs 938) ;
Gluckman, Eliane (Centre Scientifique de Monaco) ;
Nagler, Arnon (The Chaim Sheba Medical Center) ;
Universitat Autònoma de Barcelona
Nonrelapse mortality (NRM) is the first cause of treatment failure after unrelated cord blood transplantation (UCBT) following myeloablative conditioning (MAC). In the last decade, reduced-intensity conditioning (RIC) regimens have been developed with the aim of reducing NRM and allowing older patients and those with medical comorbidities to benefit from UCBT. [...]
2016 - 10.18632/oncotarget.9599
Oncotarget, Vol. 7 Núm. 28 (2016) , p. 43027-43038
|
|
|
3.
|
|
9 p, 1.0 MB |
Improved survival after acute graft-versus-host disease diagnosis in the modern era
/
Khoury, Hanna J. (Winship Cancer Institute of Emory University) ;
Wang, Tao (Medical College of Wisconsin) ;
Hemmer, Michael T. (Medical College of Wisconsin) ;
Couriel, Daniel (Utah Blood and Marrow Transplant) ;
Alousi, Amin (The University of Texas MD Anderson Cancer Center) ;
Cutler, Corey (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Battiwalla, Minoo (Lung and Blood Institute-NIH) ;
Cahn, Jean-Yves (University Hospital) ;
Cairo, Mitchell (New York Medical College) ;
Chen, Yi-Bin (Massachusetts General Hospital) ;
Gale, Robert Peter (Imperial College London) ;
Hashmi, Shahrukh (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Hayashi, Robert J. (Washington University School of Medicine in St. Louis) ;
Jagasia, Madan (Vanderbilt University Medical Center) ;
Juckett, Mark (University of Wisconsin Hospital and Clinics) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Kharfan-Dabaja, Mohamed (H. Lee Moffitt Cancer Center and Research Institute) ;
Litzow, Mark (Mayo Clinic Rochester) ;
Majhail, Navnnet (Cleveland Clinic Taussig Cancer Institute) ;
Miller, Alan (Baylor College of Medicine) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center and Research Institute) ;
Qayed, Muna (Emory University School of Medicine) ;
Antin, Joseph H. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Schoemans, Helene (University Hospitals Leuven (Bèlgica)) ;
Schouten, Harry C. (Academische Ziekenhuis) ;
Socie, Gerard (Hopital Saint Louis) ;
Storek, Jan (University of Calgary) ;
Verdonck, Leo (Isala Clinics Zwolle) ;
Vij, Ravi (Washington University School of Medicine) ;
Wood, Willian A. (University of North Carolina) ;
Yu, Lolie (Children's Hospital/Louisiana State University Medical Center) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Carabasi, Matthew (Thomas Jefferson University Hospital) ;
Dandoy, Christopher (Cincinnati Children's Hospital Medical Center) ;
Gergis, Usama (New York Presbyterian Hospital/Weill Cornell Medical Center) ;
Hematti, Peiman (University of Wisconsin Hospital and Clinics) ;
Solh, Melham (The Blood and Marrow Transplant Group of Georgia) ;
Jamani, Kareem (University of Calgary) ;
Lehmann, Leslie (Boston Children's Hospital (Boston, Estats Units d'Amèrica)) ;
Savani, Bipin (Vanderbilt University Medical Center) ;
Schultz, Kirk R. (The University of British Columbia) ;
Wirk, Baldeep M. (Seattle Cancer Care Alliance) ;
Spellman, Stephen (Center for International Blood and Marrow Transplant Research) ;
Arora, Mukta (University of Minnesota Medical Center) ;
Pidala, Joseph (H. Lee Moffitt Cancer Center and Research Institute) ;
Universitat Autònoma de Barcelona
Acute graft-versus-host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances have resulted in improved outcome specifically among those diagnosed with acute graft-versus-host disease. [...]
2017 - 10.3324/haematol.2016.156356
Haematologica, Vol. 102 Núm. 5 (30 2017) , p. 958-966
|
|
|
4.
|
|
13 p, 1.7 MB |
A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation
/
Cremers, Eline M.P. (VU University Medical Centre) ;
de Witte, Theo (Radboud University Medical Centre) ;
de Wreede, Liesbeth C. (Leiden University Medical Center) ;
Eikema, Diderik-Jan (EBMT Statistical Unit Data Office Leiden) ;
Koster, Linda (EBMT Data Office Leiden) ;
van Biezen, Anja (EBMT Data Office Leiden) ;
Finke, Jürgen (University of Freiburg) ;
Socié, Gerard (Hospital St. Louis) ;
Beelen, Dietrich (University Hospital) ;
Maertens, Johan (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Nagler, Arnon (Chaim Sheba Medical Center (Israel)) ;
Kobbe, Guido (Heinrich Heine Universitaet) ;
Ziagkos, Dimitris (EBMT Statistical Unit Data Office Leiden) ;
Itälä-Remes, Maija (HUCH Comprehensive Cancer Center) ;
Gedde-Dahl, Tobias (Oslo University Hospital (Oslo, Noruega)) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Niederwieser, Dietger (University Hospital Leipzig) ;
Ljungman, Per (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Beguin, Yves (University of Liège) ;
Ozkurt, Zubeyde Nur (Gazi University) ;
Anagnostopoulos, Achilles (George Papanicolaou General Hospital (Tessalònia, Grècia)) ;
Jindra, Pavel (Charles University Hospital) ;
Robin, Marie (Hospital St. Louis) ;
Kröger, Nicolaus (University Hospital Eppendorf) ;
Universitat Autònoma de Barcelona
Most myelodysplastic syndromes (MDS)-patients receive multiple red blood cell transfusions (RBCT). Transfusions may cause iron-related toxicity and mortality, influencing outcome after allogeneic HSCT. [...]
2019 - 10.1080/10428194.2019.1594215
Leukemia and Lymphoma, Vol. 60 Núm. 10 (2019) , p. 2404-2414
|
|
|
5.
|
|
13 p, 850.9 KB |
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation
/
Chhabra, Saurabh (Medical College of Wisconsin) ;
Liu, Ying (Medical College of Wisconsin) ;
Hemmer, Michael T. (Medical College of Wisconsin) ;
Costa, Luciano (University of Alabama at Birmingham. Department of Medicine) ;
Pidala, Joseph A. (H. Lee Moffitt Cancer Center and Research Institute) ;
Couriel, Daniel R. (Utah Blood and Marrow Transplant Program) ;
Alousi, Amin M. (University of Texas MD Anderson Cancer Center) ;
Majhail, Navneet S. (Cleveland Clinic Taussig Cancer Institute) ;
Stuart, Robert K. (Medical University of South Carolina) ;
Kim, Dennis (Princess Margaret Cancer Center) ;
Ringden, Olle (Karolinska Institutet (Estocolm, Suècia). Division of Therapeutic Immunology) ;
Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Saad, Ayman (University of Alabama at Birmingham) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Cooper, Brenda (University Hospitals Case Medical Center. Department of Medicine-Hematology and Oncology) ;
Marks, David I. (University Hospitals Bristol NHS Trust) ;
Socie, Gerard (Hôpital Saint Louis. Department of Hematology) ;
Schouten, Harry C. (Academische Ziekenhuis. Department of Hematology) ;
Schoemans, Helene (University Hospitals Leuven (Bèlgica)) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Yared, Jean (University of Maryland. Greenebaum Cancer Center) ;
Cahn, Jean-Yves (CHU Grenoble Alpes. Department of Hematology) ;
Wagner, John (Thomas Jefferson University. Department of Medical Oncology) ;
Antin, Joseph H. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Verdonck, Leo F. (Isala Clinic. Departmentt of Hematology/Oncology) ;
Lehmann, Leslie (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
MacMillan, Margaret L. (University of Minnesota Blood and Marrow Transplant Program) ;
Litzow, Mark R. (Mayo Clinic Rochester. Division of Hematology and Transplant Center) ;
Solh, Melhem M. (Northside Hospital. Blood and Marrow Transplant Group of Georgia) ;
Qayed, Muna (Emory University School of Medicine. Department of Pediatrics) ;
Hematti, Peiman (University of Wisconsin) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Vij, Ravi (Washington University School of Medicine. Division of Hematology and Oncology) ;
Hayashi, Robert J. (Washington University School of Medicine in St. Louis. Division of Pediatric Hematology/Oncology) ;
Gale, Robert Peter (Imperial College London. Hematology Research Centre) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Seo, Sachiko (National Cancer Research Center East) ;
Hashmi, Shahrukh K (Mayo Clinic Rochester. Division of Hematology and Transplant Center) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center and Research Institute) ;
Teshima, Takanori (Kyushu University Hospital) ;
Gergis, Usama (New York Presbyterian Hospital/Weill Cornell Medical Center. Department of Medical Oncology) ;
Inamoto, Yoshihiro (National Cancer Center Hospital) ;
Spellman, Stephen R. (Center for International Blood and Marrow Transplant Research) ;
Arora, Mukta (University of Minnesota Medical Center) ;
Hamilton, Betty K. (Cleveland Clinic Taussig Cancer Institute) ;
Universitat Autònoma de Barcelona
The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT), but there are limited data comparing efficacy of the 2 regimens. [...]
2019 - 10.1016/j.bbmt.2018.08.018
Biology of blood and marrow transplantation, Vol. 25 Núm. 1 (january 2019) , p. 73-85
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
